UNSPSC 51332852: Fluphenazine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOU145W1XL, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine dihydrochloride, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02232MIG.

UNSPSC 51332852 Fluphenazine hydrochloride is a Commodity code whose recent state and local activity shows little relevance to the nominal product. The three recent opportunities tagged to this code—Seminole County's naloxone and drug deactivation systems procurement (IFB), Texas HHS's therapeutic pharmacy initiative RFI, and Minnesota MMCAP's multi-source generics and OTC products RFP—do not target fluphenazine hydrochloride specifically. Instead, they reflect broader pharmaceutical procurement by state health agencies, county health departments, and cooperative purchasing alliances seeking to source controlled substances, naloxone, OTC products, or to gather market intelligence on direct-to-manufacturer pharmacy models. State and local solicitation activity in pharmaceutical procurement spans health departments and state Medicaid administrators issuing RFPs and RFQs for volume purchases, often through cooperative purchasing agreements such as MMCAP that pool demand across multiple jurisdictions and states.

Recent procurement activity under this code appears in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023—note date inconsistency in source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Minnesota's MMCAP, administered by the Department of Administration, issued an RFP in January 2026 (responses due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effective July 1, 2026. The MMCAP procurement uses price-competitiveness weighting (75 percent) and requires cGMP certification and Drug Supply Chain Security Act compliance. The mismatch between the code's nominal scope and actual recent solicitation content suggests this code is not a reliable indicator of current state and local procurement need for fluphenazine hydrochloride specifically.